SOPHiA Genetics applies AI techniques to DNA sequencing in order help doctors make better decisions in diagnosing and caring for their patients. The Switzerland-based firm founded in 2011 scooped up $77 million in its latest funding round.
Samara Rosenfeld wrote about SOPHiA for Healthcare Analytics News:
The company has now raised a total of $140 million in funding and plans to use the most recent funding to grow the number of hospitals using its technology and to expand their team.
Funding was led by Generation Investment Management, with additional investments from Idinvest Partners and existing investors Balderton Capital and Alychlo. “With Generation’s support, we will enable the more rapid adoption of data-driven medicine technology in healthcare for the benefit of patients worldwide,” said Jurgi Camblong, Ph.D., CEO and founder of SOPHiA Genetics.
Its platform, SOPHiA AI, is used by more than 850 hospitals across 77 countries and has supported the diagnoses of more than 300,000 patients. SOPHiA AI aids healthcare professionals to make sense of complex genomic and radiomic data through analysis to drive better diagnosis and treatment for patients with oncology or hereditary disorders.
